Basic HTML Version
122
SCIENTIFIC REPORT 2012
Title:
Prospective, multicenter, randomized, open, parallel group, controlled trial
to evaluate the efficacy and safety of oral rivaroxaban (BAY 59-7939) once daily
compared with oral vitamin K antagonists in adjusted doses for prevention
of cardiovascular events in patients with scheduled non-valvular uricular fibrillation
to be subjected to cardioversion.
District Attorney:
Bayer Healthcare AG.
Principal Investigator:
Eva Guillaume Gasa.
Title:
Randomized, double-blind, placebo-controlled trial with parallel groups for
evaluate the effect of SAR236553 / REGN727 on the occurrence of events
cardiovascular disease in patients who have recently experienced coronary syndrome
acute.
District Attorney:
Sanofi-Aventis Research & Development.
Principal Investigator:
Gabriel Gusi Swallowing.
Title:
European multinational registry on the prevention of thromboembolic events in
atrial fibrillation.
District Attorney:
Daiichi Sankyo Pharma Development.
Principal Investigator:
Gabriel Gusi Swallowing.
Title:
AssEssment of CoMorbidities & Atrial ArRhythmiA Burden In DalL Chamber PaceD
Patients. EMERALD study.
District Attorney:
SORIN CRM
Principal Investigator:
Gabriel Gusi Swallowing.
Title:
Multicenter study, randomized, with active control of efficacy and safety that
compare betrixaban in prolonged treatment with Enoxaparin® as a regular treatment
for the prevention of venous thromboembolism in medically ill patients
acute.
District Attorney:
Portola Pharmaceuticals, Inc.
Principal Investigator:
Ignacio Martín-Loeches.
Title:
Early treatment of Atrial fibrillation for Stroke prevention Trial.
District Attorney:
AFNET.
Principal Investigator:
Antonio Martínez Rubio.